Quick Answer
VACCINEX, INC. reported Cash and Equivalents of $1.11 million for fiscal year 2024.
VACCINEX, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $1.11M | -27.9% |
| 2023 | $1.53M | -76.0% |
| 2022 | $6.39M | -25.6% |
| 2021 | $8.59M | -18.9% |
| 2020 | $10.60M | +281.7% |
| 2019 | $2.78M | -50.6% |
| 2018 | $5.62M | +34.4% |
| 2017 | $4.18M | +151.7% |
| 2016 | $1.66M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $2.91M | +2188.2% | +1147.2% |
| June 30, 2024 | $233.0K | -87.8% | -92.2% |
| March 31, 2024 | $2.97M | -10.6% | +93.6% |
| December 31, 2023 | $1.53M | -76.0% | +1108.7% |
| September 30, 2023 | $127.0K | -98.2% | -93.3% |
| June 30, 2023 | $1.91M | -83.3% | -42.6% |
| March 31, 2023 | $3.32M | -80.2% | -48.0% |
| December 31, 2022 | $6.39M | -25.6% | -11.1% |
- VACCINEX, INC. showed a decrease of -27.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2024 period, VACCINEX, INC.’s cash and equivalents has declined by 33.4% (from $1.66 million to $1.11 million).
- The most recent figure is from VACCINEX, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: